I believe it was wise for IPIX to PR a statement

I believe it was wise for IPIX to PR a statement regarding the DoD conference cancelation. The fact that the conference was cancelled due to an explosion of the Delta variant is just another proof point for the dire need for an effective CV19 therapeutic. Leo took the opportunity to remind investors that Brilacidin continues to show consistently positive in vitro results against a wide variety of viruses. Delta virus testing is in the queue and IMO will show the same result that Brilacidin penetrates the viral wall and destroys the virus. There will most likely be some real world proof points as well with some of the Russian patients treated in the human trial that likely had the Delta variant.

If you google some of the tested H-CoV strains mentioned in today’s PR (OC43, 229E, NL63), they are species of coronavirus responsible for bronchiolitis, croup, upper and lower respiratory tract infections including pneumonia, and are among the known viruses that cause the common cold. What do you think the overall market is for treating these conditions? Do you think there might be some interest to quickly fund and develop other delivery methods such as an inhaler to address these common ailments and diseases?

IMO the DoD is completely aware of Brilacidin as a Bio Defense asset. They are anxiously awaiting B-CV19 human trial results for final confirmation like all of us investors are. What is clear from today’s PR is that if trial results are positive, there will be enormous demand to fund, procure, partner and accelerate Brilacidin to market.

I expect that IPIX will soon PR that the human trial database has been locked. Within a month or so we will get top line results. My bet is that results will be somewhere in the very good to excellent range. There are many proof points including previous Brilacidin human trials, exhaustive RBL testing specific to CV19, extraordinary Selectivity Index, unique virocidal MOA (penetrates viral wall and kills the virus) and a continual safety profile including the DMC green light to increase frequency dosing form 3 to 5 days.

I understand that some investors are impatient. I initiated my position in CTIX 10 years ago. Investors have experienced blatant criminal attacks on IPIX for over 6 years. Our time is coming very soon. IMO we are part owners of a drug that will save millions of people worldwide and have significant economic impact. We will have confirmation of this very soon and I believe that is when the fun just begins.